Pharmaceutical marketer Pfizer has resumed advertising for its controversial painkiller Celebrex, whose ads were pulled in December 2004 after charges that the drug could cause heart attacks. The ...
In the case of Celebrex, the National Cancer Institute, which was conducting the study for Pfizer, found that patients in the clinical trial taking 800 milligrams of Celebrex had 3.4 times greater ...
NEW YORK (Reuters) - Ads for Pfizer Inc.'s Celebrex arthritis drug are set to splash across U.S. television screens on Monday after more than a two-year hiatus, with an unusual upfront focus on its ...
The Celebrex warning comes little more than two months after its one-time competitor, Vioxx, was pulled from store shelves for the same concerns. "We thought Celebrex was safe and the problem was just ...
In the case of Celebrex, the National Cancer Institute suspended the use of the drug after discovering that patients taking the largest doses 400 to 800 milligrams a day had a 2.5 times greater risk ...
In the case of Celebrex, the National Cancer Institute, which was conducting the study for Pfizer, found that patients in the clinical trial taking 800 milligrams of Celebrex had 3.4 times greater ...
The National Institutes of Health, which suspended the cancer study, ordered a full review of all studies involving the cox-2 drugs. The Celebrex warning comes little more than two months after its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback